Barclays
NMRA icon

Barclays’s Neumora Therapeutics NMRA Stock Holding History

Barclays’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$113K Buy
66,226
+31,719
+92% +$60.4K ﹤0.01% 3983
2026
Q1 		$67.3K Buy
34,507
+3,583
+12% +$9.29K ﹤0.01% 4194
2025
Q4 		$55.4K Buy
30,924
+20,683
+202% +$45.3K ﹤0.01% 4721
2025
Q3 		$18.6K Sell
10,241
-2,469
-19% -$3.99K ﹤0.01% 4950
2025
Q2 		$9.32K Sell
12,710
-94,025
-88% -$71.2K ﹤0.01% 4921
2025
Q1 		$107K Sell
106,735
-60,087
-36% -$103K ﹤0.01% 4383
2024
Q4 		$1.77M Buy
166,822
+37,612
+29% +$451K ﹤0.01% 2976
2024
Q3 		$1.71M Buy
129,210
+100,678
+353% +$1.17M ﹤0.01% 2980
2024
Q2 		$280K Buy
28,532
+18,110
+174% +$187K ﹤0.01% 3380
2024
Q1 		$143K Sell
10,422
-10,117
-49% -$164K ﹤0.01% 4286
2023
Q4 		$350K Buy
+20,539
New +$252K ﹤0.01% 4108

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Barclays's NMRA Position: Q2 2026 in Review

Barclays increased its Neumora Therapeutics (NMRA) stake by 92% in Q2 2026, buying an estimated $60.4K and bringing the position to 66,226 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #3983.

Barclays first reported a position in NMRA in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.77M in Q4 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Barclays held 66,226 shares of Neumora Therapeutics worth $113K as of Q2 2026.
  • Barclays bought 31,719 Neumora Therapeutics shares in Q2 2026, an estimated $60.4K.
  • Neumora Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3983 holding.
  • Barclays first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Barclays's Neumora Therapeutics position peaked at $1.77M in Q4 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.